NCT06050122 2025-10-14
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Sol-Gel Technologies, Ltd.
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed
NCT01383538 2017-08-08
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed
NCT01130142 2017-03-06
A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
Infinity Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01255800 2014-01-31
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
University of Colorado, Denver
Phase 1 Completed
NCT01310816 2013-12-05
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT01609179 2012-11-14
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
Infinity Pharmaceuticals, Inc.
Phase NA Completed
NCT00761696 2012-06-21
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
Infinity Pharmaceuticals, Inc.
Phase 1 Completed